Baxter International Inc (BAX) Holdings Raised by TCW Group Inc.

Share on StockTwits

TCW Group Inc. boosted its holdings in shares of Baxter International Inc (NYSE:BAX) by 4.4% in the 3rd quarter, Holdings Channel reports. The fund owned 104,572 shares of the medical instruments supplier’s stock after buying an additional 4,448 shares during the quarter. TCW Group Inc.’s holdings in Baxter International were worth $8,062,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Natixis increased its stake in Baxter International by 62.5% during the second quarter. Natixis now owns 716,411 shares of the medical instruments supplier’s stock worth $52,900,000 after acquiring an additional 275,452 shares during the last quarter. AMP Capital Investors Ltd increased its stake in Baxter International by 1.5% during the second quarter. AMP Capital Investors Ltd now owns 267,439 shares of the medical instruments supplier’s stock worth $19,749,000 after acquiring an additional 3,839 shares during the last quarter. Putnam Investments LLC increased its stake in Baxter International by 33.9% during the second quarter. Putnam Investments LLC now owns 1,330,139 shares of the medical instruments supplier’s stock worth $98,217,000 after acquiring an additional 336,950 shares during the last quarter. Dakota Wealth Management acquired a new stake in Baxter International during the second quarter worth $517,000. Finally, Swiss National Bank increased its stake in Baxter International by 6.1% during the second quarter. Swiss National Bank now owns 2,191,439 shares of the medical instruments supplier’s stock worth $161,816,000 after acquiring an additional 125,700 shares during the last quarter. 83.08% of the stock is owned by institutional investors.

Several research firms have recently commented on BAX. ValuEngine lowered Baxter International from a “buy” rating to a “hold” rating in a research report on Thursday. JPMorgan Chase & Co. raised their price target on Baxter International from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, July 27th. Citigroup raised their price target on Baxter International from $74.00 to $76.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 31st. Morgan Stanley raised their price target on Baxter International from $68.00 to $75.00 and gave the stock an “underweight” rating in a research report on Thursday, October 11th. Finally, Zacks Investment Research lowered Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 24th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $77.77.

In related news, Director Carole J. Shapazian sold 5,400 shares of Baxter International stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $72.97, for a total value of $394,038.00. Following the completion of the transaction, the director now directly owns 15,248 shares in the company, valued at $1,112,646.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Giuseppe Accogli sold 17,647 shares of Baxter International stock in a transaction on Monday, September 17th. The shares were sold at an average price of $77.27, for a total value of $1,363,583.69. Following the completion of the transaction, the senior vice president now owns 59,452 shares of the company’s stock, valued at $4,593,856.04. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.

BAX opened at $62.51 on Thursday. The firm has a market cap of $36.68 billion, a PE ratio of 25.21, a PEG ratio of 1.86 and a beta of 0.77. Baxter International Inc has a 52 week low of $61.05 and a 52 week high of $78.38. The company has a quick ratio of 2.00, a current ratio of 2.62 and a debt-to-equity ratio of 0.39.

Baxter International (NYSE:BAX) last released its earnings results on Wednesday, October 31st. The medical instruments supplier reported $0.80 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.06. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.79 billion. Baxter International had a return on equity of 16.63% and a net margin of 8.29%. Baxter International’s revenue was up 2.2% compared to the same quarter last year. During the same period last year, the business posted $0.64 earnings per share. Equities research analysts predict that Baxter International Inc will post 2.98 earnings per share for the current fiscal year.

About Baxter International

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Read More: Trading Penny Stocks

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply